prikaz prve stranice dokumenta Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
  Preuzmi
PDF 305.16 KB
Znanstveni rad - Pregledni rad
Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
Acta clinica Croatica, 63. (2024), 2; 436-449. https://doi.org/10.20471/acc.2024.63.02.22
Jančuljak, Davor; Petravić, Damir; Mahović Lakušić, Darija; Lovrenčić-Huzjan, Arijana; Bačić Baronica, Koraljka; Bosnar Puretić, Marijana; Hucika, Zlatko; Titlić, Marina; Popović, Zvonimir; Tomić, Zoran; Stojić, Maristela; Bašić Kes, Vanja

Citirajte ovaj rad

Jančuljak, D., Petravić, D., Mahović Lakušić, D., Lovrenčić Huzjan, A., Bačić Baronica, K., Bosnar Puretić, M. ... Bašić Kes, V. (2024). Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab). Acta clinica Croatica, 63.. (2), 436-449. doi: 10.20471/acc.2024.63.02.22

Jančuljak, Davor, et al. "Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)." Acta clinica Croatica, vol. 63., br. 2, 2024, str. 436-449. https://doi.org/10.20471/acc.2024.63.02.22

Jančuljak, Davor, Damir Petravić, Darija Mahović Lakušić, Arijana Lovrenčić Huzjan, Koraljka Bačić Baronica, Marijana Bosnar Puretić, Zlatko Hucika, et al. "Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)." Acta clinica Croatica 63., br. 2 (2024): 436-449. https://doi.org/10.20471/acc.2024.63.02.22

Jančuljak, D., et al. (2024) 'Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)', Acta clinica Croatica, 63.(2), str. 436-449. doi: 10.20471/acc.2024.63.02.22

Jančuljak D, Petravić D, Mahović Lakušić D, Lovrenčić Huzjan A, Bačić Baronica K, Bosnar Puretić M, i sur.. Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab). Acta clinica Croatica [Internet]. 2024. [pristupljeno 27.02.2025.];63.(2):436-449. doi: 10.20471/acc.2024.63.02.22

D. Jančuljak, et al., "Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)", Acta clinica Croatica, vol. 63., br. 2, str. 436-449, 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:190557. [Citirano: 27.02.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:190557
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
Naslov (hrvatski)Hrvatske smjernice za specifično profilaktičko liječenje migrene monoklonskim protutijelima na peptid povezan s kalcitoninskim genom (CGRP) (eptinezumab, fremanezumab i galkanezumab) i na CGRP receptor (erenumab)
AutorDavor Jančuljak
AutorDamir Petravić
AutorDarija Mahović Lakušić
AutorArijana Lovrenčić-Huzjan
AutorKoraljka Bačić Baronica
AutorMarijana Bosnar Puretić
AutorZlatko Hucika
AutorMarina Titlić
AutorZvonimir Popović
AutorZoran Tomić
AutorMaristela Stojić
AutorVanja Bašić Kes
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za neurologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Neurologija
Sažetak (engleski)
Calcitonin gene-related peptide (CGRP) plays a key role in the pathophysiology of migraine, acting on CGRP receptors in the trigeminovascular system, causing neurogenic inflammation and vasodilation, and promoting nociception. Four specific monoclonal antibodies targeting CGRP are available for prevention of episodic and chronic migraine in adults with at least four migraine days per month. The aim of these guidelines is to provide evidence-based recommendations for the use of monoclonal antibodies targeting CGRP in migraine prevention in Croatia. The questions were formulated using the Patients, Intervention, Comparison, Outcome (PICO) criteria, with evidencebased answers. To assess the quality of scientific evidence, a review of the literature available in PubMed was performed. Relevant studies were reviewed by the Expert Group of the Headache Section of the Croatian Neurological Society, and served as the basis for formulating the recommendations outlined in these guidelines. We found high quality evidence for good safety and efficacy of anti- CGRP monoclonal antibodies in the preventive treatment of episodic and chronic migraine. These medications may be considered as first-line prophylactic therapy depending on the patient’s history, concomitant diseases, and disease burden. Further real-world studies are needed to elucidate other aspects of their application.
Sažetak (hrvatski)
Peptid povezan s kalcitoninskim genom (CGRP) igra ključnu ulogu u patofiziologiji migrene djelujući na CGRP receptore u trigeminovaskularnom sustavu, time uzrokujući neurogenu upalu i vazodilataciju, uz promociju nocicepcije. Četiri specifična monoklonska protutijela koja djeluju na CGRP su dostupna u profilaksi epizodne i kronične migrene u odraslih osoba s najmanje četiri migrenozna dana na mjesec. Cilj ovih smjernica je pružiti preporuke zasnovane na dokazima za primjenu monoklonskih protutijela koja djeluju na CGRP u prevenciji migrene u Hrvatskoj. Pitanja su formulirana primjenom kriterija PICO (Patients, Intervention, Comparison, Outcome), uz odgovore zasnovane na dokazima. Kako bismo procijenili kvalitetu znanstvenih dokaza pretražili smo literaturu u bazi podataka PubMed. Pronađene relevantne studije analizirala je Stručna skupina Sekcije za glavobolju Hrvatskoga neurološkog društva i služile su kao osnova za oblikovanje preporuka navedenih u ovim smjernicama. Pronašli smo visokokvalitetne dokaze u smislu dobre sigurnosti i učinkovitosti monoklonskih protutijela na CGRP u profilaksi epizodne i kronične migrene. Ovi lijekovi se mogu razmatrati u prvoj liniji profilaktičke terapije, ovisno o bolesnikovoj povijesti bolesti, supostojećim bolestima i opterećenosti bolešću. Daljnje studije u kliničkim uvjetima potrebne su kako bi se rasvijetlili dodatni aspekti njihove primjene.
Ključne riječi (engleski)
Ključne riječi (hrvatski)
Jezikengleski
Jezikhrvatski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaActa clinica Croatica
Brojčani podacivol. 63., br. 2, str. 436-449
p-ISSN0353-9466
e-ISSN1333-9451
DOIhttps://doi.org/10.20471/acc.2024.63.02.22
URN:NBNurn:nbn:hr:184:190557
Datum objave publikacije2024
URL dokumentahttps://hrcak.srce.hr/328166
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2025-02-27 14:25:08